Anti CD39 mAb IPH5201 at EMSO 2020
Meet us at BIO-Europe 2020, October 26-29
1 October 2020
Season’s greetings
15 December 2020
1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours.
